United Kingdom
Search    
Include All CSL Behring Country Sites

News

04.04.2013
European Commission Grants Marketing Authorisation to CSL Behring’s Privigen® in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring announced today that the European Commission has granted marketing authorisation for the use of Privigen® (human normal immunoglobulin, IVIg) 10 percent liquid in the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). More.

03.04.2013
CSL Behring Donates Medicine Used in Treating Bleeding Disorders to World Federation of Hemophilia
As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Haemophilia Day this month. More.

21.01.2013
CSL Behring enrolls first patient in global paediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat haemophilia
CSL Behring has announced that the first patient has been enrolled in the pivotal paediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). More.

14.01.2013
CSL Behring Seeks Proposals for the Third Annual Interlaken Leadership Awards
Committed to improving the quality of life for people with rare and serious diseases, CSL Behring is calling for proposals for the 2013 Interlaken Leadership Awards. More.

19.12.2012
Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Significantly Reduces Need for Transfusion after Aortic Surgery
Haywards Heath, UK –December 19, 2012–Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line haemostatic therapy in bleeding patients undergoing aortic replacement surgery. More.

02.07.2012
CSL Behring launches new Hizentra®▼ dosing calculator app for healthcare professionals on the move
CSL Behring UK Ltd today announce the launch of the Hizentra Dosing Calculator App at The British Society for Allergy and Clinical Immunology (BSACI) Annual Scientific Meeting, taking place in Nottingham. The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering its product Hizentra (human normal immunoglobulin, SCIg) More.

27.06.2012
CSL Behring launches new Beriplex® P/N dosing calculator app for healthcare professionals on the move
CSL Behring UK Ltd today announce the launch of the Beriplex P/N Dosing Calculator App at The General Anaesthetists in Training Annual Scientific Meeting, taking place in Glasgow. The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering its product Beriplex P/N (human prothrombin complex concentrate). More.

27.06.2012
PRIMA study shows treatment with Privigen® improved function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen® (human normal immunoglobulin) 10% Liquid, an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). More.

29.02.2012
CSL Behring supports Rare Disease Day 2012
CSL Behring UK Ltd today announced it will be supporting Rare Disease Day 2012 on 29th February. Rare Disease Day is an annual event to raise awareness of rare diseases across the globe with the ultimate aim of ensuring that rare diseases are a priority for government and health departments. More.